Cardiff Oncology, Inc. (CRDF) Earnings History
Net Loss21 years of earnings data (2005–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Cardiff Oncology, Inc. (CRDF) Earnings Overview
As of October 3, 2026, Cardiff Oncology, Inc. (CRDF) reported trailing twelve-month net income of -$40M, reflecting +27.4% year-over-year growth. The company earned $-0.59 per diluted share over the past four quarters, with a net profit margin of -7732.0%.
Looking at the long-term picture, CRDF's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2011.
Cardiff Oncology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including TGTX ($441M net income, 72.6% margin), MGNX (-$15M net income, -49.9% margin), NKTR (-$157M net income, -297.1% margin), CRDF has room to improve margins relative to the peer group. Compare CRDF vs TGTX →
CRDF Earnings vs Peers
Earnings metrics vs comparable public companies
CRDF Historical Earnings Data (2005–2025)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$46M | -0.9% | -$49M | $-0.69 | -7732.0% | -8256.3% |
| 2024 | -$45M | -9.6% | -$49M | $-0.95 | -6651.7% | -7123.1% |
| 2023 | -$41M | -7.1% | -$45M | $-0.93 | -8492.0% | -9305.7% |
| 2022 | -$39M | -36.8% | -$40M | $-0.89 | -10026.9% | -10337.3% |
| 2021 | -$28M | -46.5% | -$29M | $-0.73 | -7880.5% | -8037.6% |
| 2020 | -$19M | -17.6% | -$19M | $-1.08 | -5275.1% | -5214.8% |
| 2019 | -$16M | +0.3% | -$17M | $-2.70 | -6709.7% | -6817.8% |
| 2018 | -$16M | +33.9% | -$17M | $-7.06 | -4354.8% | -4511.4% |
| 2017 | -$25M | +36.5% | -$26M | $-51.71 | -4932.1% | -5068.5% |
| 2016 | -$39M | -42.7% | -$40M | $-93.22 | -10289.8% | -10536.7% |
| 2015 | -$27M | -91.8% | -$25M | $-74.77 | -8776.7% | -8074.8% |
| 2014 | -$14M | -21.3% | -$15M | $-54.08 | -5116.1% | -5337.5% |
| 2013 | -$12M | -2.1% | -$11M | $-50.09 | -4555.9% | -4123.7% |
| 2012 | -$12M | -416.5% | -$5M | $-63.73 | -2570.2% | -1077.6% |
| 2011 | -$2M | +58.9% | -$3M | $-16.60 | -868.9% | -1155.2% |
| 2010 | -$5M | -119.7% | -$5M | $-54.81 | -2051.1% | -2024.8% |
| 2009 | -$2M | +68.4% | -$2M | $-35.43 | -381.5% | -367.7% |
| 2005 | -$8M | - | -$8M | $-7.55 | - | - |
Download Data
Export CRDF earnings history in CSV or JSON format
Free sign-in required to download data
CRDF Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
21+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CRDF — Frequently Asked Questions
Quick answers to the most common questions about buying CRDF stock.
What is CRDF earnings per share (EPS)?
CRDF trailing twelve-month (TTM) diluted EPS is $-0.59, reflecting +27.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2005 to 2025 is available in the table on this page.
What is Cardiff Oncology, Inc.'s net income?
Cardiff Oncology, Inc. (CRDF) trailing twelve-month net income is $-40M as of 2025. Earnings grew +27.4% year-over-year.
Is CRDF profitable?
CRDF is not currently profitable on a TTM basis, reporting a net loss of $-40M. Net margin is -7732.0%. Investors should monitor for a return to profitability.
What is CRDF's earnings growth rate?
CRDF compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2005 to 2025.
What are CRDF's profit margins?
Cardiff Oncology, Inc. net profit margin is -7732.0%, operating margin is -8256.3%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -71.5%.
Is CRDF growing earnings?
Yes, CRDF earnings are accelerating — EPS growth of +27.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-40M. Earnings momentum is strengthening.
What was CRDF's best earnings year?
Cardiff Oncology, Inc.'s highest annual net income on record is $-2M, achieved in fiscal year 2011. Earnings history on this page spans 2005 to 2025 and includes all annual and quarterly figures.
What were CRDF's earnings last quarter?
CRDF's most recent reported quarter was Q2 2026. Net income was $-9M with diluted EPS of $-0.14. For a full breakdown of all quarters, see the quarterly earnings table on this page.